Raymond C. DabneyWe have paid for medications, flights, hotels, and incidentals for some.
We have helped a number of cancer patients who according to them had...We have paid for medications, flights, hotels, and incidentals for some.
We have helped a number of cancer patients who according to them had nowhere else to turn.
We have done Great work killing cancer and we can be very Proud.
We are now transitioning into formal clinical trials, this is completely different from a regulatory perspective, there are certain rules and guidelines you must follow.
Our in-house observational studies are based on a case by case as needed basis event. Individually or in groups.
We (Cannabis Science) benefit from the real world usage results, just as we have been doing all along with all our operational initiatives whether they succeed or fail.
We have learned many different perspectives and pathways within this massive brand new industry through all our observational studies.
Being one of the first successful drug development companies in this industry and being a leader because of our successes over the last ten years has its ups and downs. We learn from both and focus on the ups.
We have not launched any new observational studies in the past year or so. We will do so as the need arises through the CBIS-EDP. and it will.
We are focused heavy on this step of the transition, which is a privately held clinical drug development holdings Company that has many options.